P16 - Revision history

Michael at 16:16, 17 March 2025

2025-03-17T16:16:59Z

← Older revision		Revision as of 16:16, 17 March 2025
Line 42:		Line 42:
	Image:Consistent with HPV-associated SCC - p16 -- high mag.jpg \| c/w HPV-assoc. SCC - p16 - high mag. (WC/Nephron)		Image:Consistent with HPV-associated SCC - p16 -- high mag.jpg \| c/w HPV-assoc. SCC - p16 - high mag. (WC/Nephron)
	</gallery>		</gallery>

	===Penile cancer===		===Penile cancer===
	*p16 is considered surrogate for HPV and ''block-type positivity'' is considered indicative of HPV.<ref name=pmid36221864>{{cite journal \|authors=Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, Compérat E, Hartmann A, Netto G, Rubin MA, Gill AJ, Turajlic S, Tan PH, Raspollini MR, Tickoo SK, Amin MB \|title=WHO 2022 classification of penile and scrotal cancers: updates and evolution \|journal=Histopathology \|volume=82 \|issue=4 \|pages=508–520 \|date=March 2023 \|pmid=36221864 \|doi=10.1111/his.14824 \|url=}}</ref>		*p16 is considered surrogate for HPV and ''block-type positivity'' is considered indicative of HPV.<ref name=pmid36221864>{{cite journal \|authors=Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, Compérat E, Hartmann A, Netto G, Rubin MA, Gill AJ, Turajlic S, Tan PH, Raspollini MR, Tickoo SK, Amin MB \|title=WHO 2022 classification of penile and scrotal cancers: updates and evolution \|journal=Histopathology \|volume=82 \|issue=4 \|pages=508–520 \|date=March 2023 \|pmid=36221864 \|doi=10.1111/his.14824 \|url=}}</ref>
	*~~An older~~ meta-analysis shows that p16 staining criteria ~~are not firmly established~~.		**A meta-analysis from 2018 shows that various p16 staining criteria have been used in the past.<ref name=pmid29987099>{{cite journal \|authors=Sand FL, Rasmussen CL, Frederiksen MH, Andersen KK, Kjaer SK \|title=Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis \|journal=Cancer Epidemiol Biomarkers Prev \|volume=27 \|issue=10 \|pages=1123–1132 \|date=October 2018 \|pmid=29987099 \|doi=10.1158/1055-9965.EPI-18-0322 \|url=}}</ref>

	<pre>		<pre>

Michael at 16:14, 17 March 2025

2025-03-17T16:14:19Z

← Older revision		Revision as of 16:14, 17 March 2025
Line 43:		Line 43:
	</gallery>		</gallery>
	===Penile cancer===		===Penile cancer===
	*p16 is considered surrogate for HPV and ''block-type positivity'' is considered indicative of HPV.<ref name=pmid36221864>{{cite journal \|authors=Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, Compérat E, Hartmann A, Netto G, Rubin MA, Gill AJ, Turajlic S, Tan PH, Raspollini MR, Tickoo SK, Amin MB \|title=WHO 2022 classification of penile and scrotal cancers: updates and evolution \|journal=Histopathology \|volume=82 \|issue=4 \|pages=508–520 \|date=March 2023 \|pmid=36221864 \|doi=10.1111/his.14824 \|url=}}<ref>		*p16 is considered surrogate for HPV and ''block-type positivity'' is considered indicative of HPV.<ref name=pmid36221864>{{cite journal \|authors=Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, Compérat E, Hartmann A, Netto G, Rubin MA, Gill AJ, Turajlic S, Tan PH, Raspollini MR, Tickoo SK, Amin MB \|title=WHO 2022 classification of penile and scrotal cancers: updates and evolution \|journal=Histopathology \|volume=82 \|issue=4 \|pages=508–520 \|date=March 2023 \|pmid=36221864 \|doi=10.1111/his.14824 \|url=}}</ref>
	*An older meta-analysis shows that p16 staining criteria are not firmly established.		*An older meta-analysis shows that p16 staining criteria are not firmly established.

Michael at 16:13, 17 March 2025

2025-03-17T16:13:17Z

← Older revision		Revision as of 16:13, 17 March 2025
Line 42:		Line 42:
	Image:Consistent with HPV-associated SCC - p16 -- high mag.jpg \| c/w HPV-assoc. SCC - p16 - high mag. (WC/Nephron)		Image:Consistent with HPV-associated SCC - p16 -- high mag.jpg \| c/w HPV-assoc. SCC - p16 - high mag. (WC/Nephron)
	</gallery>		</gallery>
			===Penile cancer===
			*p16 is considered surrogate for HPV and ''block-type positivity'' is considered indicative of HPV.<ref name=pmid36221864>{{cite journal \|authors=Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, Compérat E, Hartmann A, Netto G, Rubin MA, Gill AJ, Turajlic S, Tan PH, Raspollini MR, Tickoo SK, Amin MB \|title=WHO 2022 classification of penile and scrotal cancers: updates and evolution \|journal=Histopathology \|volume=82 \|issue=4 \|pages=508–520 \|date=March 2023 \|pmid=36221864 \|doi=10.1111/his.14824 \|url=}}<ref>
			*An older meta-analysis shows that p16 staining criteria are not firmly established.

			<pre>
			The p16 staining is patchy (~10% of tumour) and moderate. The 2022 WHO Classification describes "block-type positivity" as being relevant; as such, the case is interpreted as p16 NEGATIVE.

			HPV testing will be requested and the findings reported in an addendum.
			</pre>

	==Positive==		==Positive==
	*[[Squamous cell carcinoma]] - esp. [[cervical SCC]], anal SCC, penile SCC, [[HPV-associated head and neck SCC]].		*[[Squamous cell carcinoma]] - esp. [[cervical SCC]], anal SCC, penile SCC, [[HPV-associated head and neck SCC]].

Michael: /* Positive */

2021-11-25T15:59:54Z

Positive

← Older revision		Revision as of 15:59, 25 November 2021
Line 51:		Line 51:

	Note:		Note:
	*Positive staining the (head and neck pathology) ~~context~~ is defined as (strong block) positive staining in >50% (or >75%) of lesional cells.<ref>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>		*Positive staining (in the head and neck pathology context) is defined as (strong block) positive staining in >75% (or >50%) of lesional cells.<ref name=pmid28621317>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>
	**Staining varies somewhat by the p16 clone used.		**Staining varies somewhat by the p16 clone used.

Michael: /* Positive */

2021-11-23T16:03:06Z

Positive

← Older revision		Revision as of 16:03, 23 November 2021
Line 51:		Line 51:

	Note:		Note:
	*Positive staining the (head and neck pathology) context is defined as strong block positive staining in >50% (or >75%) of lesional cells.<ref>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>		*Positive staining the (head and neck pathology) context is defined as (strong block) positive staining in >50% (or >75%) of lesional cells.<ref>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>
	**Staining varies somewhat by the p16 clone used.		**Staining varies somewhat by the p16 clone used.

Michael: /* Positive */

2021-11-23T16:02:28Z

Positive

← Older revision		Revision as of 16:02, 23 November 2021
Line 51:		Line 51:

	Note:		Note:
	*Positive staining the (head and neck pathology) context is defined as strong block positive staining in >50% of lesional cells.<ref>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>		*Positive staining the (head and neck pathology) context is defined as strong block positive staining in >50% (or >75%) of lesional cells.<ref>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>
			**Staining varies somewhat by the p16 clone used.

	===Benign===		===Benign===

Michael: /* Positive */

2021-11-23T16:00:23Z

Positive

← Older revision		Revision as of 16:00, 23 November 2021
Line 49:		Line 49:
	**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.		**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.
	*[[Small cell carcinoma of the lung]] - most cases (95 of 101 cases in one series<ref name=pmid29566943>{{cite journal \|authors=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).		*[[Small cell carcinoma of the lung]] - most cases (95 of 101 cases in one series<ref name=pmid29566943>{{cite journal \|authors=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).

			Note:
			*Positive staining the (head and neck pathology) context is defined as strong block positive staining in >50% of lesional cells.<ref>{{cite journal \|authors=Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS \|title=p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status \|journal=Mod Pathol \|volume=30 \|issue=9 \|pages=1194–1203 \|date=September 2017 \|pmid=28621317 \|doi=10.1038/modpathol.2017.31 \|url=}}</ref>

	===Benign===		===Benign===

Michael: /* Positive */

2020-12-31T15:39:33Z

Positive

← Older revision		Revision as of 15:39, 31 December 2020
Line 48:		Line 48:
	*[[High-grade squamous intraepithelial lesion]] - full thickness, strong.		*[[High-grade squamous intraepithelial lesion]] - full thickness, strong.
	**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.		**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.
	*[[Small cell carcinoma of the lung]] - most cases (95 of 101 cases in one series<ref name=pmid29566943>{{cite journal \|~~vauthors~~=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).		*[[Small cell carcinoma of the lung]] - most cases (95 of 101 cases in one series<ref name=pmid29566943>{{cite journal \|authors=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).

	===Benign===		===Benign===

Michael: /* Positive */

2020-12-31T15:38:58Z

Positive

← Older revision		Revision as of 15:38, 31 December 2020
Line 48:		Line 48:
	*[[High-grade squamous intraepithelial lesion]] - full thickness, strong.		*[[High-grade squamous intraepithelial lesion]] - full thickness, strong.
	**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.		**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.
	*[[Small cell carcinoma of the lung]] (95 of 101 cases<ref name=pmid29566943>{{cite journal \|vauthors=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).		*[[Small cell carcinoma of the lung]] - most cases (95 of 101 cases in one series<ref name=pmid29566943>{{cite journal \|vauthors=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).

	===Benign===		===Benign===

Michael: /* Positive */

2020-12-31T15:37:55Z

Positive

← Older revision		Revision as of 15:37, 31 December 2020
Line 48:		Line 48:
	*[[High-grade squamous intraepithelial lesion]] - full thickness, strong.		*[[High-grade squamous intraepithelial lesion]] - full thickness, strong.
	**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.		**A subset of LSIL stains with p16; however, it is ''not'' full thickness - see ''[[HSIL]]'' article.
			*[[Small cell carcinoma of the lung]] (95 of 101 cases<ref name=pmid29566943>{{cite journal \|vauthors=Švajdler M, Mezencev R, Ondič O, Šašková B, Mukenšnábl P, Michal M \|title=P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens \|journal=Ann Diagn Pathol \|volume=33 \|issue= \|pages=23–29 \|date=April 2018 \|pmid=29566943 \|doi=10.1016/j.anndiagpath.2017.11.008 \|url=}}</ref>).

	===Benign===		===Benign===